Thierry Voisin

Thierry Voisin

Auto-generated profile, based on publicly available information

Thierry Voisin

Toulouse University Hospital

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in The Journal of nutrition, health and aging
Verified
Journal Article
Open access
PDF file
TVT. Voisin
T. Voisin
SAS. Andrieu
S. Andrieu
CCC. Cantet
C. Cantet
BVB. Vellas
B. Vellas
RGREAL.FR Group
REAL.FR Group
During the course of the Alzheimer’s disease (AD), many patients need to be hospitalized either due to the direct consequences of the disease itself, or due to associated diseases or life event. The objective of the present study was to determine predictive factors for hospitalisation in AD patients.

1 March 2011 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
JDJulien Delrieu
Julien Delrieu
APAntoine Piau
Antoine Piau
CCCéline Caillaud
Céline Caillaud
TVThierry Voisin
Thierry Voisin
BVBruno Vellas
Bruno Vellas

1 December 2009 in The Journal of nutrition, health and aging
Verified
Journal Article
Open access
PDF file
TVT. Voisin
T. Voisin
SSS. Sourdet
S. Sourdet
CCC. Cantet
C. Cantet
SAS. Andrieu
S. Andrieu
BVB. Vellas
B. Vellas
RGReal-Fr Goup
Real-Fr Goup
There is lack of data on the frequency and the causes of hospitalization in mild to moderate Alzheimer’s disease (AD) patients. The aims of the present study were to evaluate the frequency and the causes of hospitalization in a large prospective cohort of mild to moderate patients with AD.

19 October 2020 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
JDJulien Delrieu
Julien Delrieu
TVThierry Voisin
Thierry Voisin
LSLaure Saint-Aubert
Laure Saint-Aubert
ICIsabelle Carrie
Isabelle Carrie
CCChristelle E. Cantet
Christelle E. Cantet
SASandrine Andrieu
Sandrine Andrieu
Background: The Multidomain Alzheimer Preventive Trial (MAPT) was designed to assess the efficacy of omega-3 fatty acid supplementation, multidomain intervention (MI), or a combination of both on cognition. Although the MAPT study was negative, an effect of MI in maintaining cognitive functions compared to placebo group was showed in positive amyloid subjects. A FDG PET study (MAPT-NI) was implemented to test the impact of MI on brain glucose metabolism. Methods: MAPT-NI was a randomized, controlled parallel-group single-center study, exploring the effect of MI on brain glucose metabolism. Participants were non-demented and had memory complaints, limitation in one instrumental activity of daily living, or slow gait. Participants were randomly assigned (1:1) to “MI group” or “No MI group.” The MI consisted of group sessions focusing on 3 domains: cognitive stimulation, physical activity, nutrition, and a preventive consultation. [18F]FDG PET scans were performed at baseline, 6 months, and 12 months, and cerebral magnetic resonance imaging scans at baseline. The primary objective was to evaluate the MI effect on brain glucose metabolism assessed by [18F]FDG PET imaging at 6 months. The primary outcome was the quantification of regional metabolism rate for glucose in cerebral regions involved early in Alzheimer disease by relative semi-quantitative SUVr (FDG-based AD biomarker). An exploratory voxel-wise analysis was performed to assess the effect of MI on brain glucose metabolism without anatomical hypothesis. Results: The intention-to-treat population included 67 subjects (34 in the MI group and 33 in the No MI group. No significant MI effect was observed on primary outcome at 6 months. In the exploratory voxel-wise analysis, we observed a difference in favor of MI group on the change of cerebral glucose metabolism in limbic lobe (right hippocampus, right posterior cingulate, left posterior parahippocampal gyrus) at 6 months. Conclusions: MI failed to show an effect on metabolism in FDG-based AD biomarker, but exploratory analysis suggested positive effect on limbic system metabolism. This finding could suggest a delay effect of MI on AD progression. Trial registration: ClinicalTrials.gov Identifier, NCT01513252.

1 December 2003
Verified
Journal Article
Closed access
TVThierry Voisin
Thierry Voisin
JTJacques Touchon
Jacques Touchon
BVBruno Vellas
Bruno Vellas